LEADER 04285nam 2200601 a 450 001 9910140908703321 005 20200520144314.0 010 $a0-470-92271-0 010 $a1-282-88898-6 010 $a9786612888984 010 $a0-470-91001-1 010 $a0-470-91000-3 035 $a(CKB)2670000000054603 035 $a(EBL)698739 035 $a(OCoLC)696237308 035 $a(SSID)ssj0000439559 035 $a(PQKBManifestationID)12157214 035 $a(PQKBTitleCode)TC0000439559 035 $a(PQKBWorkID)10476399 035 $a(PQKB)10415497 035 $a(MiAaPQ)EBC698739 035 $a(Au-PeEL)EBL698739 035 $a(CaPaEBR)ebr10441458 035 $a(CaONFJC)MIL288898 035 $a(PPN)243268459 035 $a(EXLCZ)992670000000054603 100 $a20100507d2011 uy 0 101 0 $aeng 135 $aurcn#---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aMetabolic syndrome$b[electronic resource] $eunderlying mechanisms and drug therapies /$fedited by Minghan Wang 210 $aHoboken, N.J. $cJohn Wiley & Sons$dc2011 215 $a1 online resource (510 p.) 300 $aDescription based upon print version of record. 311 $a0-470-34342-7 320 $aIncludes bibliographical references and index. 327 $aGut as an endocrine organ : the role of nutrient-sensing in energy metabolism / Minghan Wang -- Central glucose sensing and control of food intake and energy homeostasis / Lourdes Mounien and Bernard Thorens -- Abnormalities in insulin secretion in type 2 diabetes mellitus / Taly Meas and Pierre-Jean Guillausseau -- Adipokine production by adipose tissue : a novel target for treating metabolic syndrome and its sequelae / Vanessa DeClercq ... [et al.] -- Hepatic metabolic dysfunctions in type 2 diabetes : insulin resistance and impaired glucose production and lipid synthesis / Ruojing Yang -- Energy metabolism in skeletal muscle and its link to insulin resistance / Minghan Wang -- Mechanisms and complications of metabolic syndrome / Minghan Wang -- Emerging therapeutic approaches for dyslipidemia associated with high LDL and low HDL / Margrit Schwarz and Jae B. Kim -- Mechanism of action of niacin : implications for atherosclerosis and drug discovery / Devan Marar ... [et al.] -- Current anti-diabetic therapies and mechanisms / Minghan Wang -- GLP-1 biology, signaling mechanisms, physiology, and clinical studies / Remy Burcelin ... [et al.] -- Dipeptidyl peptidase IV inhibitors for treatment of diabetes / McIntosh, C.H.S. ... [et al.] -- Sodium glucose co-transporter 2 inhibitors / Margaret Ryan and Serge A. Jabbour -- Fibroblast growth factor 21 as a novel metabolic regulator / Radmila Micanovic, James D. Dunbar, and Alexei Kharitonenkov -- Sirtuins as potential drug targets for metabolic diseases / Qiang Tong -- 11-hydroxysteroid dehydrogenase type 1 as a therapeutic target for type 2 diabetes / Clarence Hale and David J. St. Jean, Jr -- Monoclonal antibodies for the treatment of type 2 diabetes : a case study with glucagon receptor blockade / Hai Yan, Wei Gu, and Murielle Veniant-Ellison -- Drug development for metabolic diseases: past, present and future / Minghan Wang. 330 $aThis book provides a comprehensive overview of the development of metabolic syndrome, the underlying mechanisms and therapeutic strategies for drug development. The authors examine the context of underlying molecular pathways and integrated physiology, then expanding the discussion to diseases associated with metabolic syndrome. The development of drug therapies for these diseases and complications is extensively covered. The book offers a comprehensive and in-depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism-based drug discovery and clinical implications. 606 $aMetabolic syndrome$xPathophysiology 606 $aMetabolic syndrome$xChemotherapy 615 0$aMetabolic syndrome$xPathophysiology. 615 0$aMetabolic syndrome$xChemotherapy. 676 $a616.3/99 701 $aWang$b Minghan$f1966-$0902785 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910140908703321 996 $aMetabolic syndrome$92018116 997 $aUNINA